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1. Introduction  
In 2010 alone there were an estimated 54,000 new diagnoses and 12,000 deaths attributable 
to renal cell carcinoma (RCC), with the vast majority of these tumors consituting small renal 
masses incidentially detected on cross-sectional imaging.(2010; Chow, Dong, and Devesa, 
2010)  Renal cortical tumors include a complex family of neoplasms with unique histology, 
cytogenetic effects, and metastatic potential; the differential presentation of symptomatic, 
locally advanced disease as opposed to small renal tumors (median tumor size <4cm, T1a) 
evokes different management paradigms.(Lee et al., 2010; McKiernan et al., 2002b; Mitchell 
et al., 2006; Russo et al., 2002)  This large subcategory of patients with localized RCC have 
historically been treated with radical nephrectomy, and this management has continued in 
many regions of the United Stes and the world.(Hollenbeck et al., 2006)  Nevertheless, a 
paradigm shift has occured in the surgical management of renal cortical tumors over the last 
10 years, favoring nephron-sparing surgery or partial nephrecotmy whenever this approach 
is feasible from a technical and oncologic standpoint.  The rationale underpinning this shift 
has involved the observed non-inferiority in terms of cancer control and operative morbidity 
as well as the superior renal functional outcomes.  Within the neprhology and urology 
communities, the last decade has also witnessed a increased understanding of how renal 
volume effects renal function, and how this in turn affects cardiovascular competence.  It 
now is evident that having less renal parenchyma does not only worsen renal function, but 
it also is a poor prognosticator of cardiac function and overall survival.  It is within this 
context that a review of renal functional outcomes following surgery for renal coritcal 
tumors can be undertaken.       
2. Renal cancer: Changing epidemiology 
Approximately 75-80% of patients in the United States with renal cancer are now diagnosed 
incidentally and with organ-confined disease.  This shift is largely attributable to the 
increasing use of cross-sectional imaging with the utilization of CT and MRI increasing by 
73% during 1986-1994 among the Medicare population.  Furthermore, depending on the 
histologic sub-type, the prognosis ranges from 75-100% of patients achieving long-term 
survival, and an estimated 30% of patients over 70 years of age dying of unrelated causes 
within 5 years of surgery for a renal cortical neoplasm.(Jewett and Zuniga, 2008)  The 
increased incidence and detection of these cancers is largely due to the diagnosis of small 
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localized renal lesions, many of which have low metastatic potential.  This finding is 
reflected in the fact that mortality as a result of renal cancer has not changed over time 
despite the increased incidence. (Figure 1) 
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Fig. 1. Trends in Renal Cancer Over Time, American Cancer Society, Facts & Figures,  
1997-2006 
In parallel with the impetus underlying the increased detection of renal neoplasms, the 
detection of benign renal lesions, defined chiefly as oncocytoma, angiomyolipoma, and 
simple renal cysts, has also increased.  In fact, a contemporary review of the Columbia 
University experience identified 775 patients with a tumor diameter of less than or equal to 
7.0 cm.  Of these patients the proportion of patients undergoing renal surgery for benign 
tumors increased annually: 5% before 1998, 15.2% from 1998-2003, and 21.2% from 2004 to 
2007.  The mean tumor diameter was found to decrease significantly during the study 
period (p=0.006) and year of surgery and tumor diameter were found to be independent 
predictors of benign histologic features (p<0.05).(Murphy et al., 2009) 
This combination of observations thus underscores the changing phenomenology of renal 
cortical lesions, as an increase in the use of cross-sectional imaging has resulted in a higher 
proportion of patients with incidentally detected small renal masses and in turn the clinical 
recognition of benign renal pathology.   
2.1 Renal cortical tumors: Heterogeneous presentations and oncologic implications 
Renal cortical tumors are members of a complex category of histologic entities which 
includes the benign oncocytoma, the indolent papillary and chromophobe carcinomas, and 
also the potentially aggressive clear cell carcinoma.  While published urological series 
consist predominantly of small, localized renal masses, approximately 90% of the medical 
oncology series reporting metastatic renal cancers consist of tumors of conventional clear 
cell histology.  In fact, a retrospective review by McKiernan et al featured 246 consecutive 
partial nephrectomy specimens, and characterized the relative distribution of histologic 
subtypes in small renal masses.(McKiernan et al., 2002b)  Within this series from Memorial 
Sloan Kettering Cancer Center, the most frequent finding was conventional clear cell 
carcinoma in 148 cases (51%), followed by papillary carcinoma in 54 (18%), oncocytoma in 
32 (11%), and chromophobe in 21 (7%).      
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The World Health Organization (WHO)/ Heidelberg classification subdivides renal cell 
tumors into benign and malignant neoplasms based on documented genetic 
abnormalities.(Kovacs et al., 1997)  In fact, studies focusing on sporadic and hereditary 
forms of renal cancer have suggested that abnormalities in the von Hippel-Lindau 
(chromosome 3p) and met genes are among the earliest alterations in conventional clear cell 
and papillary renal cancers, respectively.  Table 1 highlights the major chromosomal 
alterations that have been implicated in different renal cortical neoplasms. 
 
Histological 
Subtype 
Early Genetic/ 
Molecular 
Defects 
Late Genetic/ 
Molecular Defects 
Associated 
Syndromes 
Conventional 
LOH 3p 
Mutation of 3p25 
(VHL) 
+5p 
-8p, -9p, -14q 
P53 mutationC-
erB-1 Oncogene 
Von Hippel-
Lindau 
Sporadic RCC 
Hereditary RCC 
Papillary 
+7, +17 
-Y 
Met gene 
mutation 
+12, +16, +20 
-9p, -11q, -14q, -
17p, -21q 
PRCC-TFE3 gene 
fusion 
Hereditary 
Papillary (HPRC) 
Sporadic 
Papillary 
Chromophobe -1 
-1p, -2p, -6p, -13q, 
-21q, -Y 
p53 Mutation 
 
Collecting Duct -18, -Y 
-1q, -6p, -8p, -11, -
13q, -21q 
C-erB-1 
Renal Medullary 
Carcinoma 
Oncocytoma 
-1, -Y, 11q 
rearrangement 
 
Familial 
Oncocytoma 
Table. 1. Genetic Findings in Renal Carcinoma Subtypes. Zambrano et al. J Urol 1999; 163 (4): 
1246-58 adapted by P. Russo, MD.  
Later work demonstrated that pathologic tumor diameter may be useful in the prediction of 
conventional subtype in small renal cortical lesions.  One retrospective review involved 393 
patients who underwent radical or partial nephrectomy at one institution; logistic regression 
analysis demonstrated that for every 1cm increase in tumor diameter up to 4cm, the renal 
cortical lesion was 1.27 times more likely to be conventional clear cell (p=0.020).(Laudano et 
al., 2008)  These findings were extrapolated to show that a 4cm renal cortical tumor was 
approximately 2 times more likely to be conventional clear cell than tumors 0.6-1.5cm in 
size. (Figure 2) 
3. Partial nephrectomy is the standard of care for small renal masses (T1a) 
Radical nephrectomy became the standard of care for renal cortical neoplasms approximately 
40 years ago. In the 1980s this approach was challenged by reports demonstrating favourable 
results of partial nephrectomy in imperative cases (i.e. cases in which nephron-sparing surgery 
was mandatory to conserve adequate renal function such as in patients with a solitary 
kidney).(Novick et al., 1989; Zincke et al., 1985)  During the last 10 years partial nephrectomy 
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Fig. 2. The percentage of conventional clear cell renal carcinomas based on largest tumor 
diameter (*rounded to the nearest cm). Laudano et al. BJU Int. 2008; 102 (10): 1385-8. 
has become the standard of care for the management of most small renal masses even in the 
presence of a normal contralateral kidney.(Becker et al., 2006b; Huang et al., 2006; Patard et 
al., 2004; Thompson et al., 2005)  In addition to the benefits of preserving renal function and 
preventing cardiovascular complications, topics discussed in detail in the ensuing sections, 
evidence strongly supports the notion that cancer control and risk of cancer-related death 
are not compromised when a partial nephrectomy is performed instead of a radical 
procedure.(Dash et al., 2006; Leibovich et al., 2004)  
Although data from the National Cancer Institute SEER program demonstrated that partial 
nephrectomy was underutilized at the beginning of this century (2000-2002), with only 20% 
of patients with tumors 2-4cm in size receiving this procedure, these rates are changing in 
favour of a nephron-sparing approach.(Hollenbeck et al., 2006; Miller et al., 2006)  In fact, a 
retrospective review of 1,533 patients treated with partial or radical nephrectomy between 
2000-2007 at Memorial Sloan Kettering Cancer Center reported that nephron-sparing 
surgery was performed in approximately 90% of patients with T1a tumors.(Thompson et al., 
2009)  A similar analysis at the national level is documented in Figure 3, demonstrating that 
the use of partial nephrectomy is increasing, albeit at a relatively modest rate, with 66% of 
patients presenting with a renal cortical tumor <2cm in size receiving a partial nephrectomy 
in 2007.    
3.1 Partial nephrectomy is increasingly being utilized in medium-sized tumors (T1b) 
The current size determination for renal tumors that forms the basis for the 2010 TNM 
staging classification was founded on the basis of several studies demonstrating improved 
survival in patients undergoing surgery for tumors less than 4cm as opposed to those that 
exceeded this dimension.(Gofrit et al., 2001; Hafez, Fergany, and Novick, 1999)  More 
contemporary analyses have shown that regardless of the form of surgical intervention, 
namely partial or radical nephrectomy, patients with tumors larger than 4cm have a higher 
risk of relapse.(Lau et al., 2000; Lesage et al., 2007; Margulis et al., 2007; Mitchell et al., 2006; 
Zini et al., 2009)  On the basis of these precedents, there has been a clear impetus to 
determine whether elective nephron-sparing surgery may be an option for patient with 
localized T1b (4-7cm) tumors.   
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Fig. 3. The Current Standard of Care for the Treatment of Tumors <2cm based on 
Surveillance, Epidemiology, and End Results (SEER) estimates.  The use of PN steadily 
increased over the study period, from 27% of all cases in 1998 to 66% in 2007. Kates et al.  
J Uro 2011 IN PRESS. 
In fact, several antecedent investigations have indicated partial nephrectomy can safely be 
expanded to include patients with T1bN0M0 tumors.(Becker et al., 2006a; Kim et al., 2010; 
Mitchell et al., 2006; Patard et al., 2004)  Leibovich and colleagues reported cancer-specific 
survival rates at 5 years of 98% for those receiving nephron-sparing surgery and 86% for 
patients treated with radical nehrectomy; and, after adjusting for several covariates 
including tumor grade and histologic subtype, this difference was found to no longer be 
statistically significant (risk ratio 1.60, 95% CI 0.50-5.12, p=0.430).(Leibovich et al., 2004)  In a 
similar vein, Patard et al noted that 3 year disease-specific survival rates were comparable at 
98% and 97% (p=0.8) when partial nephrectomy patients were stratified by tumor size less 
than and greater than 4cm, respectively.(Patard et al., 2007)  Last, recent work has 
expounded upon these findings as it pertains to the laparoscopic management of T1bN0M0 
tumors, documenting comparable cancer-specific mortality (3% vs 3%) and recurrence rates 
RN 3% vs PN 6%, p-0.40) for both procedures over a median follow-up of 57 
months.(Simmons, Weight, and Gill, 2009)  These studies thus set the precedent that 
nephron-sparing surgery is a viable option form an oncologic standpoint in an 
appropriately selected subset of patients with a medium-sized tumors when treated at 
centers experienced with these techniques. 
Last, a subsequent investigation by Badalato et al. extended these findings regarding 
nephron-sparing surgery for T1b patients to the population level, utilizing data from the 
Surveillance, Epidemiology, and End Results (SEER) registry.(Badalato et al., 2011)  Using 
propensity scoring, a statistical test that controls for measured variables between partial and 
radical nephrectomy cohorts, this study determined that no overall survival difference was 
noted within a matched cohort of pT1bN0M0 patients treated with either surgical 
alternative. (Figure 4)  These findings thus lend support to the aforementioned growing 
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body of evidence that partial neprhectomy may become the preferred management 
alternative for T1b renal tumors. 
 
 
 
 
Fig. 4. Overall survival in a propensity-matched cohort of SEER patients receiving partial 
versus radical nephrectomy.  For the entire cohort, there was no difference in survival when 
groups were divided based on surgical treatment.  Badalato et al. BJU Int. 2011 IN PRESS 
4. Renal tumor patients may have unrecognized medical renal disease before 
intervention 
Patients with renal tumors are not a screened population and tend to be older (mean age 61 
years) with cardiovascular comorbidities.  Accordingly, clinical and pathological evidence 
has shown that this population of patients has a greater degree of underlying renal disease 
than previously appreciated.(Bijol et al., 2006; Kaplan et al., 1975)  In fact, a retrospective 
cohort study of patients with small renal tumors by Huang et al. showed that 26% of their 
patients with T1a RCC and normally functioning kidneys had pre-existing chronic kidney 
disease (CKD), defined as GFR <60 mL/min per 1·73 m2. (Huang et al., 2006)    
The most common renal diseases found in patients with renal tumors are due to 
hypertension and diabetes.  Bijol and colleagues reported that up to 60% of nephrectomy 
specimens show features of renal disease, most of which are due to changes from 
hypertension or diabetes. (Bijol et al., 2006) Other causes of renal disease include smoking, 
glomerulonephritis, cystic kidney diseases, congenital malformations, immune diseases, 
obstruction, and infection. 
Moreover, many of the risk factors that are implicated in the pathogenesis of renal disease 
overlap with the risk factors that contribute to renal cell carcinoma.  For example, although 
the pathophysiologic mechanism for this relationship is still unclear, there is a progressive 
increase in the risk of renal cell carcinoma in correlation with worsening hypertension. 
(Chow, Dong, and Devesa, 2010; Schlehofer et al., 1996; Setiawan et al., 2007) With regard to 
diabetes, the pre-surgical incidence of this disease ranges from 6.8% to 23%. (Hepps and 
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Chernoff, 2006; Lindblad et al., 1999; Schlehofer et al., 1996) Since diabetic nephropathy 
affects approximately one-third of patients with this condition, it is reasonable to extrapolate 
that a significant proportion of patients diagnosed with a renal cortical tumor will have pre-
existing diabetic nephropathy.  Last, smoking is another well-known risk factor prevalent 
within the population that contributes to an increased risk for the development of both renal 
disease and renal cell carcinoma. (Ejerblad et al., 2004; Hunt et al., 2005) 
Recent evidence by Donin et al. also demonstrated renal tumor diameter independently 
predicted decreased preoperative estimated GFR when controlling for hypertension and 
race on multivariable analysis. (Donin et al., 2011)  This study thus suggests that the growth 
of a renal neoplasm and perhaps the replacement of healthy renal parenchyma 
independently modulates renal functional deterioration to some degree. 
Cumulatively, the presence of underlying renal disease in patients diagnosed with a renal 
cortical neoplasm is significant because renal function plays an important role in the surgical 
management and overall survival associated with management. Therefore, it remains 
prudent to be aware of the risk of underlying renal disease in patients with RCC. 
4.1 Chronic kidney disease poses and independent risk factor for cardiovascular-
related death 
Approximately 26 million adults in the United States have CKD.  CKD is most commonly 
seen among African-Americans, Hispanics, Pacific Islanders, Native Americans, and the 
elderly. The National Kidney Foundation, American Heart Association, and the Seventh 
Joint National Committee on prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure deemed CKD as an independent risk factor for cardiovascular disease.(2002; 
Chobanian et al., 2003; Sarnak et al., 2003) Similarly, cardiovascular disease is the leading 
cause of morbidity and mortality among patients with CKD. 
The criteria for CKD is defined by The National Kidney Foundation - Kidney Disease 
Outcomes Quality Initiative (NKF-K/DOQI) workgroup (See Table 2). 
 
 
Table 2. Criteria for Definition of Chronic Kidney Disease. Am J Kidney Dis 2002 39  
(2 Suppl 1), S1-266. 
Many studies have provided evidence that renal damage, assessed by markers of renal 
function such as serum creatinine, GFR, and albuminuria, is an independent risk factor for 
cardiovascular disease and cardiovascular mortality.   
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In a study of 1,120,295 patients in the San Francisco Bay Area, Go and colleagues 
demonstrated a progressively increased risk of death and/or a cardiovascular event as renal 
function declined.  They reported that the adjusted risk of a cardiovascular event increased 
by 43% with an estimated GFR of 45 to 59 ml/minute/1.73 m2 (HR 1.4; CI 1.4-1.5) and by 
343% with an estimated GFR of less than 15 ml/minute/1.73 m2 (HR 3.43; CI 3.1-3.8).  The 
presence of proteinuria was also an independent factor that predicted the risk of a 
cardiovascular event (HR1.3; CI 1.2-1.3). (Go et al., 2004)  
Level I evidence from the Heart Outcomes Prevention Evaluation (HOPE) trial 
demonstrated that the presence of kidney disease, defined as an increased serum creatinine 
>1.4 mg/dL and/or microalbuminuria, independently increased the risk of cardiovascular 
death, myocardial infarction, or stroke (HR, 1.40; CI, 1.16-1.69 for serum creatinine) (HR 
1.59; CI 1.37- 1.84 for microalbuminuria).  Moreover, compared to patients with neither risk 
factor, patients with both increased serum creatinine and microalbuminuria were at 
increased risk of having a cardiovascular death or cardiovascular event (28.6% vs 13.6%); 
this suggests the additive nature of these risk factors. (Mann et al., 2001)  
Cumulatively, the findings from these and similar studies qualify CKD alone as a risk factor 
for cardiovascular disease. 
5. Partial nephrectomy preserves renal function 
Emerging evidence strongly favors partial nephrectomy (PN), as opposed to radical 
nephrectomy (RN), for tumors that are 7cm or smaller as the best approach to preserve 
postoperative renal functional outcomes.  The data in support of this position stemmed from 
early work examining the prevalence and onset of CKD among postoperative renal cancer 
patients.  Then, as now, there is not standardized metric of renal function, although some 
precise mechanisms of assaying such function have gradually permeated the urologic 
literature.  McKiernan et al published one of the early papers on this subject, selecting a 
cohort of 290 patients with T1a (<4cm) renal cell carcinoma and a pre-operative serum 
creatinine of less than 1.5mg/dl and then longitudinally tracking the onset of chronic renal 
insufficiency (defined in the study as creatinine >2mg/dl) following surgical 
intervention.(McKiernan et al., 2002a)  In fact, at 5 years of follow-up the rate of freedom 
from CRI was 100% in the partial nephrectomy grouping and 84.8% in the radical 
nephrectomy cohort.  Huang et al. Later validated these findings in a level 2 prospective 
study using eGFR of less than 60mL/min per 1.73m2 as the index defining CKD Stage III or 
greater.(Lane et al., 2010b)  In a total of 662 patients with a normal serum creatinine prior to 
surgery for RCC, freedom from new onset CKD was determined to be 80% after partial 
nephrectomy as opposed to just 35% following radical nephrectomy.(Huang et al., 2006) 
(Figure 5)  Moreover, after controlling for relevant clinical and pathological differences 
between surgical groups, patients receiving a radical nephrectomy were found to be a t a 
four-fold higher risk of having CKD post-operatively as compared to their counterparts 
undergoing nephron-sparing surgery.  These findings were substantiated in similar work 
using creatinine clearance as an alternative measure of renal function.(Clark et al., 2008)   
Despite controversy related to the best metric for renal functional outcomes in the 
perioperative setting, the fact that partial nephrectomy results in improved long-term renal 
function compared to radical nephrectomy has continued to be validated in the 
literature.(Jeon et al., 2009; Lane et al., 2010c; Malcolm et al., 2009; Miller et al., 2008)  In fact, 
although there was initially concern that vascular clamping at the renal hilum during partial 
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nephrectomy might increase the rate of renal insufficiency due to the prolonged cold 
ischemia time, clamp time was shown not to be associated with long-term renal functional 
measures in patients who had a normal renal function at baseline.  Yossepowitch et al. went 
on to demonstrate that in healthy patients with two renal units, renal insufficiency is 
primarily a transient, postoperative entity.(Yossepowitch et al., 2006)  While non-modifiable 
factors such as preoperative eGFR as well as the amount and quality of the renal 
parenchyma left in situ may be prognostic of postoperative renal function, there is no level 1 
evidence to further inform these notions.(Lane et al., 2011; Thompson and Blute, 2007) 
 
 
 
Fig. 5. Probability of freedom from new onset of GFR lower than 45 mL/min per 1.72m2 by 
operation type. Huang et al. Lancet Oncol 2006; 7: 735-40.  
5.1 Poor renal functional outcomes following nephrectomy increases the risk of 
cardiovascular sequelae and death  
Several prior studies have demonstrated the increase in non-cancer related deaths among 
patients undergoing radical as opposed to partial nephrectomy.(Thompson et al., 2008; 
Weight et al., 2010b)  Although it has been postulated that this increase in mortality was 
attributable to an increased rate of CKD and by extension cardiovascular disease, this theory 
had not been proven prior to the publication of recent work.  In fact, Weight, Novick, and 
colleagues examined the overall and disease-specific survival outcomes in 1,004 patients 
with T1b RCC (4-7cm) who underwent either partial or radical nephrectomy.  Over a 
median follow-up period of 4 years, a significantly decreased level of real function was 
observed in the radical nephrectomy cohort.(Weight et al., 2010a)  Furthermore, this 
difference in renal function correlated with a 25% increase in the risk of cardiovascular 
death and a 17% risk of death from any cause.  In subsequent work, Huang et al 
corroborated the results of this single-institution study with a population-level investigation 
involving Medicare beneficiaries; they found that radical nephrectomy was associated with 
an increased risk of cardiovascular events and non-cancer mortality within this 
grouping.(Huang et al., 2009)  Table 1 summarizes data that continues to emerge in 
contemporary work, substantiating the worsened overall and cardiovascular survival 
associated with radical as compared to nephron-sparing surgery. (Table 2)  
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    Patients (n) 
Overall 
Death 
CV 
Events/Death 
Study Year Age 
Tumor 
Size RN PN HR HR 
Thompson [22] 2008 <65 ≤4cm 140 187 2.16 — 
Huang [25] 2009 >65 ≤4cm 2547 556 1.38 1.4 
Weight [24] 2010 — 4-7cm 480 525 1.17 1.25 
Weight [23] 2010 — ≤7cm 111 388 2.5 — 
Table 2. Open series outcomes: Overall and Cardiovascular Mortality.  Kates et al. Curr Opin 
Urol 2011 IN PRESS 
5.1.1 Partial nephrectomy is underutilized, within certain populations: case in point – 
the elderly 
In the seminal articles on post-nephrectomy renal function published by McKiernan et al. 
and Huang et al., most of the with decompensating function were diagnosed less than 3 
years following their initial surgery.(Huang et al., 2006; McKiernan et al., 2002a)  Thus the 
concept of “long-term” benefit from a nephron-sparing approach is a fallacy, as this 
advantage is noted within a few years following surgical intervention.  An older patient, 
albeit with a shorter life expectancy may thus benefit from a partial nephrectomy.  This 
finding is especially pertinent since it has already been demonstrated that the risk of 
complication from a partial nephrectomy is no greater for patients over 75 years of age as 
compared to younger counterparts.(Lowrance et al., 2010)  This understanding is especially 
important due to urologists’ hesitation to perform a nephron-sparing procedure in the 
elderly – cumulatively a historic disparity which is not substantiated by an evidence-based 
approach and has persisted to this decade.(Hollenbeck et al., 2006; Kates et al., 2011) (Figure 6) 
Recently, Lane and colleagues demonstrated that a decline in renal function associated with 
a radical procedure in patients 75 years of age and older resulted in a corresponding 
increase in the risk of cardiovascular death.(Lane et al., 2010a)  In a cohort of elderly patients 
with local renal cell cancer 7cm or less, there was no statistically significant difference in 
survival for those receiving surgery, namely radical or partial nephrectomy, as opposed to 
those on active surveillance.  This finding suggests that no surgery or the proverbial 
“maximal nephron-sparing procedure” may be indicated for a carefully selected subset of 
the elderly patient population. 
6. Preoperative risk stratification schemata 
Comprehensive pre-operative risk stratification is important for patients undergoing kidney 
surgery in order to help approximate the best renal functional outcomes.  Remarkably, 
recent estimates have reported that up to one-third of patients with pre-existing Stage I or II 
CKD will progress to Stage II (GFR<60).(Clark et al., 2011)  Accordingly, several risk factors 
for the post-operative development of stage III CKD have been well described; chief among 
them involves having a prior diagnosis of diabetes.(Lane et al., 2011)  Composite  
risk profiles have been well-elucidated to predict a patients’ risk of CKD based on 
preoperative clinical parameters.  One such method is the Screening for Occult Renal 
Disease (SCORED) tool, a modified example of which is demonstrated in figure 7.  This 
prediction tool utilizes factors such as patient age, gender, and clinical characteristics (such 
as anemia, proteinuria, and cardiovascular comorbidities) to stratify patient into risk  
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Fig. 6. Percentage of patients receiving radical nephrectomy for T1a RCC between 1998-2007 
according to tumor size.  A higher percentage of elderly patients consistently receive a 
radical nephrectomy for a given tumor size.  Kates et al. Urology 2011 IN PRESS. 
 
 
Fig. 7. Risk assessment chart for CKD using the SCORED model from Bang et al. Arch Intern 
Med 167(4), 374-81. 
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groupings for the development of CKD.  During the course of validating this instrument in 
the setting of patients with small renal masses undergoing surgery, Lucas et al determined 
that patients in high risk categories (SCORED>4) were 3 times more likely to develop Stage 
III CKD.(Bang et al., 2007; Lucas et al., 2008)  Other groups have followed suit with the 
proposal of alternative nomograms.  For example, Sorbellini et al have described a 
mechanism to predict renal insufficiency, which was defined as 2 or more values of a 
creatinine of 2.0mf/dl at least one month following surgery.(Sorbellini et al., 2006)  
Nevertheless, while this nomogram accounts for the change in renal volume, it relies on 
creatinine and does not include known predictors of CKD such as preoperative comorbidity 
information.      
Other systems of risk stratification have looked at the renal parenchyma in and of itself as a 
tool for predicting postoperative outcomes.  Notably, the presence and extent of 
glomerolosclerosis in normal parenchyma has been shown to be commensurate with 
deterioration in postoperative renal function, although this trend was not noted for features 
such as arteriosclerosis or interstitial fibrosis/ tubular atrophy.(Gautam et al., 2010; McCann 
et al., 2009) 
7. Conclusion  
Among patients diagnosed with a renal cortical neoplasm, those having a radical 
nephrectomy are at an increased risk for the development of CKD compared to those 
receiving nephron-sparing surgery or no surgery.  In parallel with these findings, the 
implications of radical nephrectomy and CKD also translate into adverse cardiovascular 
events and eventual end stage renal disease.  Accordingly, in patients presenting with a 
renal cortical mass, a comprehensive assessment of current and projected renal function is 
paramount in determining preferred management options.  
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